Compare Regeneron Pharmaceuticals Inc (REGN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Veritone Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 968.8× Veritone Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| REGN | VERI | |
|---|---|---|
Market Cap | $83.15B | $85.83M |
Sector | Health | Technology |
52-Week High | $852.03 | $8.39 |
52-Week Low | $555.51 | $0.79 |
Enterprise Value | $77.86B | $121.22M |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $111.73 million in 2025, with revenue of $92.19 million, and has missed earnings expectations in recent quarters. Recent news includes a securities class action investigation and partnerships to expand AI solutions.
Outlook remains challenged by persistent losses and legal overhangs, though cost reduction efforts and AI partnerships offer potential growth. Investment risks include high cash burn, negative margins, and shareholder litigation. Analyst sentiment is mixed with a slight buy bias, but fundamental weakness limits near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
